A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Multiple Sclerosis (MS)

In brief

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).

Key facts

Study ID

NCT03737812

Run by

AbbVie

People needed

123

Starts

2019-02-27

Expected to finish

2021-08-30

Last updated by the study team

2023-12-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of primary-progressive multiple sclerosis (PPMS) or non-relapsing secondary-progressive multiple sclerosis (SPMS) and no relapses for at least 24 months.
• Evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test.

You may not qualify if…

• Treatment with any of the following within the 6 months prior to Screening: natalizumab; cyclosporine; azathioprine; methotrexate; mycophenolate mofetil; intravenous immunoglobulin (IVIg); any interferon product; and intravenous (IV), oral, or intrathecal corticosteroids for the purposes of disease modification.
• Treatment with the following within 1 year prior to Screening: cyclophosphamide or alemtuzumab.

Where it is running

• St. Josephs Hospital and Med Center /ID# 202809 — Phoenix, Arizona, United States
• Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 202448 — Berkeley, California, United States
• The Research Center of Southern California /ID# 202802 — Carlsbad, California, United States
• Vladimir Royter MD /ID# 202483 — Hanford, California, United States
• Stanford MS Center /ID# 202445 — Palo Alto, California, United States
• UC Davis Health-Neurological Surgery /ID# 202485 — Sacramento, California, United States
• UCSF School of Medicine - Neurology /ID# 203194 — San Francisco, California, United States
• University of Colorado School of Medicine, Dept of Neurology /ID# 202807 — Aurora, Colorado, United States
• Advanced Neurosciences Research, LLC /ID# 203072 — Fort Collins, Colorado, United States
• Rowe Neurology Institute /ID# 202744 — Lenexa, Kansas, United States
• Duplicate_Parexel International /ID# 202747 — Baltimore, Maryland, United States
• International Neurorehabilitation Institute /ID# 213333 — Lutherville, Maryland, United States
• Michigan Institute for Neurological Disorders (MIND) /ID# 202470 — Farmington Hills, Michigan, United States
• Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206327 — Owosso, Michigan, United States
• Ridgeview Specialty Clinic Chaska - Neurology /ID# 204384 — Chaska, Minnesota, United States
• Washington University-School of Medicine /ID# 202899 — St Louis, Missouri, United States
• The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205432 — St Louis, Missouri, United States
• Cleveland Clinic Lou Ruvo Cent /ID# 204744 — Las Vegas, Nevada, United States
• Oklahoma Med Res. Foundation /ID# 203442 — Oklahoma City, Oklahoma, United States
• Providence Neurological Specialties - West /ID# 203193 — Portland, Oregon, United States
• Advanced Neurosciences Institute /ID# 204555 — Franklin, Tennessee, United States
• KCA Neurology - Franklin /ID# 202912 — Franklin, Tennessee, United States
• Neurology Consultants of Dallas - LBJ Fwy /ID# 203102 — Dallas, Texas, United States
• Central Texas Neurology Consul /ID# 203108 — Round Rock, Texas, United States
• Integrated Neurology Services /ID# 202743 — Alexandria, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.